Analisis Keuangan Saham MYE0 - MaxCyte, Inc. (DB) Stock

MaxCyte, Inc.
DE ˙ DB ˙ US57777K1060
€ 1.13 ↑0.01 (0.89%)
2025-09-05
BAHAGING PRESYO
Gambaran Umum
MaxCyte, Inc., headquartered in Gaithersburg, Maryland, USA, operates primarily in the biotechnology sector, where it focuses on cell engineering through its proprietary flow electroporation technology. This cutting-edge technology facilitates the development and commercialization of cell-based therapies and life science research applications. MaxCyte's notable projects include strategic collaborations with leading pharmaceutical and biotechnology companies to enhance the discovery, development, and manufacture of new therapeutics, particularly in the burgeoning field of cell therapy. The company supports advancements in drug development and cellular research by providing high-performance cell engineering solutions that are both scalable and capable of high-volume processing, thereby addressing critical needs within the biotech industry.
Skor Kualitas, Nilai, dan Momentum

Kartu ini menunjukkan skor Kualitas, Nilai, dan Momentum untuk perusahaan tersebut.

Kualitas

The QualityScore is a proprietary scoring model that identifies high quality companies, based on cash generating efficiencies.

Nilai

Model penilaian eksklusif yang memberi peringkat pada perusahaan berdasarkan valuasi relatifnya. Skor berkisar antara 0 hingga 100, dengan 100 sebagai yang paling diremehkan nilainya.

Momentum

Proprietary scoring model that ranks companies on their six-month momentum.

Sentimen Dana

Skor Sentimen Dana (sebelumnya dikenal sebagai Skor Kepemilikan) adalah model kuantitatif eksklusif yang memberi peringkat pada perusahaan berdasarkan tingkat akumulasi kepemilikan.

QVM

The QVM Score is a proprietary scoring model that combines Quality, Value, and Momentum into a single metric that ranks companies from 0 to 100.

Laporan Laba Rugi: Pendapatan, Laba Operasional, Laba Bersih
  • Nilai revenue untuk MaxCyte, Inc. per 2025 Jun 30 adalah 35.75 MM.
  • Nilai operating income untuk MaxCyte, Inc. per 2025 Jun 30 adalah -53.48 MM.
  • Nilai net income untuk MaxCyte, Inc. per 2025 Jun 30 adalah -44.77 MM.
Period End (TTM) Revenue (MM) Operating Income (MM) Net Income (MM)
2025-06-30 35.75 -53.48 -44.77
2025-03-31 37.67 -51.22 -41.79
2024-12-31 38.63 -51.20 -41.05
2024-09-30 45.60 -46.39 -35.74
2024-06-30 45.44 -46.29 -35.43
2024-03-31 44.05 -47.40 -36.57
2023-12-31 41.29 -48.30 -37.92
2023-09-30 38.05 -46.95 -37.45
2023-06-30 40.68 -40.71 -32.64
2023-03-31 41.25 -36.38 -30.39
2022-12-31 44.26 -27.36 -23.57
2022-09-30 41.99 -25.57 -23.64
2022-06-30 41.49 -20.30 -19.88
2022-03-31 38.99 -15.97 -16.04
2021-12-31 33.89 -18.19 -19.08
2021-09-30 32.26 -15.61 -16.86
2021-06-30 28.88 -16.01 -17.28
2021-03-31 26.92 -14.44 -15.86
2020-12-31 26.17 -11.06 -11.82
2020-09-30 24.28 -10.41 -10.88
2020-06-30
2020-03-31
Laporan Laba Rugi: EPS
Period End (TTM) Earnings Per Share Basic Earnings Per Share Diluted
2025-06-30
2025-03-31
2024-12-31 -0.39
2024-09-30 -0.34 -0.34
2024-06-30 -0.34 -0.34
2024-03-31 -0.35 -0.35
2023-12-31 -0.37
2023-09-30 -0.36 -0.36
2023-06-30 -0.32 -0.32
2023-03-31 -0.30 -0.30
2022-12-31 -0.23
2022-09-30 -0.23 -0.23
2022-06-30 -0.20 -0.20
2022-03-31 -0.17 -0.17
2021-12-31 -0.21 -0.21
2021-09-30 -0.20 -0.20
2021-06-30 -0.22 -0.21
2021-03-31 -0.21 -0.21
2020-12-31 -0.17 -0.17
2020-09-30 -0.17 -0.17
2020-06-30 -0.16 -0.16
2020-03-31 -0.20 -0.20
Arus Kas: Operasi, Investasi, Pendanaan
  • Nilai cash from operating activities untuk MaxCyte, Inc. per 2025 Jun 30 adalah -36.48 MM.
  • Nilai cash from investing activities untuk MaxCyte, Inc. per 2025 Jun 30 adalah 13.01 MM.
  • Nilai kas dari aktivitas pendanaan untuk MaxCyte, Inc. per 2025 Jun 30 adalah 1.18 MM.
Period End (TTM) Cash From Operating Activities (MM) Cash From Investing Activities (MM) Cash From Financing Activities (MM)
2025-06-30 -36.48 13.01 1.18
2025-03-31 -31.46 30.86 1.74
2024-12-31 -27.61 6.93 2.06
2024-09-30 -18.81 4.46 2.14
2024-06-30 -22.66 3.66 1.95
2024-03-31 -27.93 10.95 1.39
2023-12-31 -21.69 54.98 2.14
2023-09-30 -28.75 32.03 2.88
2023-06-30 -26.44 -31.46 3.28
2023-03-31 -15.41 -189.98 3.45
2022-12-31 -14.78 -24.82 2.89
2022-09-30 -9.66 -9.17 2.87
2022-06-30 -4.43 -110.84 187.01
2022-03-31 -9.73 -15.91 186.71
2021-12-31 -10.68 -195.01 234.72
2021-09-30 -11.63 -183.95 233.60
2021-06-30 -11.77 -38.26 49.28
2021-03-31 -7.93 -0.68 77.80
2020-12-31 -8.78 -16.58 28.90
2020-09-30 -8.09 -15.59 31.30
2020-06-30
2020-03-31
Metrik Penilaian: PE, PriceToBook, PriceToTBV
P/Book
The current closing price divided by the book value per share.
P/TBV
The current price divided by the tangible book value per share.
Period End (TTM) p/e P/Book P/TBV
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31
Metrik Penilaian: EBitToEv, EBit3YrAvgToEv
Period End (TTM) EBIT/EV EBIT (3y)/EV
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31
Efektivitas Manajemen
  • roa untuk MaxCyte, Inc. pada 2025 Jun 30 adalah -0.17.
  • roe untuk MaxCyte, Inc. pada 2025 Jun 30 adalah -0.20.
  • roic untuk MaxCyte, Inc. pada 2025 Jun 30 adalah -0.19.
  • croic untuk MaxCyte, Inc. pada 2025 Jun 30 adalah 0.01.
  • ocroic untuk MaxCyte, Inc. pada 2025 Jun 30 adalah -0.14.
Period End (TTM) ROA ROE ROIC (Tingkat Pengembalian Investasi Modal) CROIC OCROIC
2025-06-30 -0.17 -0.20 -0.19 0.01 -0.14
2025-03-31 -0.16 -0.18 -0.18 -0.08 -0.12
2024-12-31 -0.13 -0.18 -0.15 -0.05 -0.08
2024-09-30 -0.13 -0.15 -0.15 -0.07 -0.09
2024-06-30 -0.13 -0.15 -0.15 -0.06 -0.11
2024-03-31 -0.13 -0.15 -0.15 0.14 -0.09
2023-12-31 -0.13 -0.15 -0.15 0.02 -0.12
2023-09-30 -0.11 -0.13 -0.13 -0.21 -0.10
2023-06-30 -0.10 -0.13 -0.13 -0.21 -0.10
2023-03-31 -0.08 -0.12 -0.12 -0.76 -0.06
2022-12-31 -0.09 -0.09 -0.09 -0.06 -0.04
2022-09-30 -0.07 -0.09 -0.09 -0.06 -0.04
2022-06-30 -0.17 -0.25 -0.07 0.26 -0.02
2022-03-31 -0.20 -0.20 -0.06 0.58 -0.04
2021-12-31 -0.33 -0.57 -0.07 0.11 -0.04
2021-09-30 -0.33 -0.51 -0.06 0.14 -0.15
2021-06-30 -0.32 -0.46 -0.20 -0.01 -0.14
2021-03-31 -0.53 -1.17 -0.18 0.79 -0.09
2020-12-31 -0.39 -0.87 -0.29 0.09 -0.22
2020-09-30 -0.36 -0.80 -0.27 0.19 -0.21
2020-06-30 -0.38 -0.59 -0.21 0.60 -0.19
2020-03-31 -0.45 -0.70 -0.54 -0.09 -0.53
Gross Margins
  • marjin kotor untuk MaxCyte, Inc. pada 2025 Jun 30 adalah 0.81.
  • marjin bersih untuk MaxCyte, Inc. pada 2025 Jun 30 adalah -1.11.
  • marjin operasi untuk MaxCyte, Inc. pada 2025 Jun 30 adalah -1.36.
Margin Kotor
The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
Margin Keuntungan Bersih
Margin Bersih (juga dikenal sebagai Margin Keuntungan) adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Bersih. Perhitungannya adalah Pendapatan Bersih / Pendapatan.
Margin Operasi
Margin Operasi adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Operasi. Perhitungannya adalah Pendapatan Operasi / Pendapatan.
Period End (TTM) Margin Kotor Margin Keuntungan Bersih Margin Operasi
2025-06-30 0.81 -1.11 -1.36
2025-03-31 0.82 -1.06 -1.33
2024-12-31 0.86 -0.78 -1.02
2024-09-30 0.88 -0.78 -1.02
2024-06-30 0.88 -0.83 -1.08
2024-03-31 0.89 -0.92 -1.17
2023-12-31 0.88 -0.98 -1.23
2023-09-30 0.87 -0.80 -1.00
2023-06-30 0.88 -0.80 -1.00
2023-03-31 0.88 -0.74 -0.88
2022-12-31 0.89 -0.56 -0.61
2022-09-30 0.90 -0.56 -0.61
2022-06-30 0.90 -0.48 -0.49
2022-03-31 0.89 -0.41 -0.41
2021-12-31 0.90 -0.56 -0.54
2021-09-30 0.89 -0.52 -0.43
2021-06-30 0.89 -0.60 -0.55
2021-03-31 0.90 -0.59 -0.54
2020-12-31 0.89 -0.45 -0.42
2020-09-30 0.89 -0.45 -0.43
2020-06-30 0.89 -0.39 -0.39
2020-03-31 0.89 -0.48 -0.47
Pengenal dan Deskriptor
Kunci Indeks Pusat (CIK)1287098
Other Listings
US:MXCT US$ 1.41
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista